Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendations

An author shares his own story about the “pay me now or pay me later” relationship between cancer chemotherapy and heart disease. (Washington Post)

Three pending cases before the U.S. Supreme Court have the potential to reshape the authority of the federal agencies that regulate healthcare. (Association for Clinical Oncology)

The FDA declined to approve odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma because of slow enrollment in two confirmatory clinical trials, Regeneron announced.

Two-thirds of newborns with sickle cell disease live in counties that have high levels of social vulnerability. (Morbidity and Mortality Weekly Report)

Results of preclinical studies suggest the combination of venetoclax (Venclexta) and 5-azacitidine (Vidaza) might have substantial anticancer activity in multiple myeloma. (Royal College of Surgeons in Ireland)

A gene implicated in colon cancer may play a role in a broad range of solid tumors. (Johns Hopkins Medicine, JCO Precision Oncology)

Medexus Pharmaceuticals announced FDA approval of recombinant coagulation factor IX (Ixinity) for on-demand, prophylactic, and perioperative treatment of hemophilia B in patients younger than 12 years of age.

A Medicare policy for lung cancer screening may be “undermining the purpose for which it was created.” (Mount Sinai, Annals of Family Medicine)

A new guideline from the American Society of Clinical Oncology offers recommendations and information about vaccination of adults with cancer.

News of Kate Middleton’s cancer diagnosis has focused new attention on the puzzling rise in cancer diagnoses in younger people. (Time)

Bristol Myers Squibb announced that a pivotal trial of adagrasib (Krazati) in KRAS-mutated metastatic non-small cell lung cancer met the primary endpoint of progression-free survival.

Please enable JavaScript to view the

comments powered by Disqus.